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Background and Objectives The donor medical questionnaire is designed to aid
blood establishments in supporting a safe blood supply. According to blood
donor deferral policies, sexual risk behaviour (SRB) leads to a (temporary) defer-
ral from blood donation. This systematic review aimed to scientifically underpin
these policies by identifying the best available evidence on the association
between SRB and the risk of transfusion transmissible infections (TTIs).
Materials & Methods Studies from three databases investigating the link between
SRB (excluding men who have sex with men (MSM)) and TTIs (HBV, HCV, HIV,
Treponema pallidum) in donors from Western and Pacific countries were obtained
and assessed on eligibility by two reviewers independently. The association
between SRB and TTIs was expressed by calculating pooled effect measures via
meta-analyses. The GRADE methodology (Grades of Recommendation, Assess-
ment, Development and Evaluation) was used to assess the quality of evidence.
Results We identified 3750 references and finally included 15 observational stud-
ies. Meta-analyses showed that there is a significant (P < 005) positive associa-
tion between the following SRB and HBV and/or HCV infection: having sex with
an intravenous drug user (high-certainty evidence), receiving money or goods for
sex (moderate-high certainty evidence), having a sex partner with hepatitis/HIV
(moderate-certainty evidence) and paid for sex or anal sex (low-certainty evi-
dence).
Conclusion Sexual risk behaviour (including having sex with an intravenous
drug user, receiving money or goods for sex or having a sex partner with hepati-
tis/HIV) is probably associated with an increased risk of HBV/HCV infection in
blood donors from Western and Pacific countries.
Key words: donor health, donor recruitment, donors.
Introduction
The blood supply chain starts with the blood donor and
ends with the patient. Various factors can affect the safety
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of blood supply including a range of donor, product and
storage/handling factors. Importantly, collection of blood
only from donors who are at low risk for transfusion-trans-
mitted infections is a cornerstone of blood safety. A rigor-
ous process to assess donor’s eligibility is therefore
essential to safeguard the health of both recipients of trans-
fusion and blood donors themselves, while ensuring that
eligible donors are not deferred unnecessarily [1].
An important safety tool to assess donor eligibility is
the donor health questionnaire which primarily aims to
identify risk behaviour for potential transfusion-transmis-
sible infections (TTI) and to defer people from donation
(temporarily). Deferral policies (often of 12 months dura-
tion), for persons whose sexual behaviour puts them at
risk of acquiring TTIs, are commonly applied by blood
transfusion services in Western countries [2]. Based on
evidence from epidemiological and modelling studies, an
international working group concluded that men who
have sex with men (MSM) and commercial sex workers
are groups at risk [3]. Hence, the two main approaches
currently used for sexual behaviour eligibility assessment
are time-based deferrals after the last male-to-male sex-
ual contact and after high-risk sexual behaviour, usually
defined as new partners or multiple partners of either sex.
As proposed by EU blood directives, an evidence-based
approach is recommended for developing donor selection
criteria on the best available scientific evidence [4]. In
2015, our group published a systematic review that iden-
tified studies describing the risk of TTIs in MSM blood
donors [5]. Today, no systematic collection, synthesis and
critically appraisal of studies is available that investigates
the risk of TTIs in sexual risk behaviour other than MSM,
such as a new sexual partner, paying for sex, group sex,
multiple sex partners, received money or goods for sex,
sex with an intravenous drug user, sex with a person
infected with HBV, HCV, HIV, syphilis or other sexually
transmitted disease. This information can support blood
services and policy-makers to further scientifically under-
pin sexual risk behaviour items on the donor health ques-
tionnaire and with corresponding deferral policies.
The general aim of this systematic review was to iden-
tify and synthesize all available scientific evidence on the
association between sexual risk behaviour (excluding
MSM) and the risk of infection by transfusion-transmissi-
ble diseases in a Western blood donor population. This
review will primarily inform policy-makers on donor
selection by the Belgian Red Cross and other European
blood services.
Material & methods
We carried out a systematic literature review according to
a predefined protocol [6]. We planned and reported the
systematic review in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analy-
ses (PRISMA checklist, Appendix S1) [7].
Data sources and searches
A literature search was performed in MEDLINE (via the
PubMed interface), Embase (via Embase.com) and the
Cochrane Library for eligible studies from the time of
inception of the database until April 2017. We developed
search strategies for each database including the use of
index terms and free text terms (Appendix S2). Search
yields were exported to a citation program (EndNote
X75), duplicates were discarded, and title and abstract
screening was initiated. The reference lists of included
studies and also the first 20 similar articles in PubMed
were screened for other relevant publications.
Study selection
Studies were eligible for inclusion if they answered the fol-
lowing PICO question: “Is sexual risk behaviour (interven-
tion/risk factor) a risk factor for transfusion-transmissible
infections (TTIs) (outcome) compared to no sexual risk
behaviour (comparison) in blood donors from Western and
Pacific countries (population)?” The review was restricted
to original articles published in English, French and Dutch.
Relevant other foreign language references were assessed
and potentially included if an English, Dutch or French title
and/or abstract was available. Full texts of potentially rele-
vant articles were reviewed according to the following
inclusion and exclusion criteria:
Population
Inclusion: Blood donors, living in areas most relevant for
our Blood Service, that is the following Western and Pacific
countries according to the Cold War definition of Samuel P
Huntington [8]: Northern, Western, and Southern Europe
(Albania, Andorra, Austria, Belgium, Bosnia and Herzegov-
ina, Croatia, Denmark, Estonia, Finland, France, Germany,
Gibraltar, Greece, Iceland, Italy, Ireland, Kosovo, Latvia,
Liechtenstein, Lithuania, Luxembourg, Macedonia, Malta,
Monaco, Montenegro, the Netherlands, Norway, Poland,
Portugal, San Marino, Serbia, Slovenia, Spain, Sweden,
Switzerland, United Kingdom, Vatican City), the USA,
Canada, Australia and New Zealand. Exclusion: Popula-
tions that were potentially eligible to give blood but not
explicitly defined as blood donors, and populations con-
taining blood donors but not exclusively blood donors.
Intervention/Risk factor
Inclusion: sexual risk behaviour such as a new sexual
partner, paying for sex, group sex, multiple sex partners,
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received money or goods for sex, sex with an intravenous
drug user, sex with a person infected with HBV, HCV,
HIV, syphilis or other sexually transmitted disease. Exclu-
sion: Men who had sex with men (risk factor that was
studied in another systematic review [5]). We excluded
composite measures that combined different sexual risk
behaviour factors (e.g. sexual promiscuity) or composite
measures that combined a sexual risk behaviour factor of
interest with another risk factor (e.g. sex with an intra-
venous drug user combined with number of men who
had sex with men).
Comparison
Inclusion: no sexual risk behaviour.
Outcome
Inclusion: markers of TTIs from the following pathogenic
microorganisms in the blood: HIV, HBV, HCV and Tre-
ponema pallidum (causing syphilis).
Study design
Inclusion: Experimental studies: randomised controlled
trials, controlled clinical trials, before- and after-studies;
Observational studies: cohort studies and case–control
studies. Exclusion: Non-controlled studies, cross-sectional
studies without appropriate analysis (i.e. case–control
analysis), case reports, case series, letters, comments,
opinion pieces and narrative reviews.
Two reviewers independently performed the title and
abstract screening followed by the full-text assessment
according to these inclusion and exclusion criteria. Dis-
agreements were resolved by discussion or by consulting
a third reviewer.
Data extraction
Data concerning study design, population characteristics,
risk factor (i.e. sexual risk behaviour), outcome measures
(markers of TTIs expressed as risk ratio, odds ratio or
incidence ratio) and study quality were extracted inde-
pendently by two reviewers. In the case that studies
reported both unadjusted as well as adjusted effect
measures, only the adjusted effect measures were
extracted.
Grading of the evidence
The GRADE approach (Grading of Recommendations,
Assessment, Development and Evaluation) was used to
assess the certainty of the evidence [9]. The certainty of
the evidence was graded as high, moderate, low or very
low. Observational studies (e.g. case–control studies)
receive an initial grade of low by default and are down-
graded based on the following prespecified criteria: (1)
limitations in study design in case the following items
were present in the majority of studies: inappropriate eli-
gibility criteria, inappropriate methods for exposure and
outcome variables, not controlled for confounding,
incomplete or inadequate follow-up, (2) inconsistency
(substantial unexplained inter-study heterogeneity, I2
>50% and P < 010), (3) indirectness (presence of factors
that limit the generalizability of the results), (4) impreci-
sion (limited total population size or limited number of
events (n < 300), and/or large 95% confidence intervals
(no effect + relative risk reduction/increase >25%) and (5)
publication bias (significant evidence of small-study
effects). Three prespecified criteria might upgrade the cer-
tainty of the evidence: when a large magnitude of effect,
with no plausible confounding, exists (upgrade with one
level in case of a large effect (OR = 2–5), upgrade with
two levels in case of a very large effect (OR > 5)), when
there is a dose–response gradient or when all plausible
confounders or other biases increase our confidence in
the estimated effect.
Data synthesis
Review Manager 53 was used to perform meta-analyses.
Heterogeneity was assessed by inspection of the forest
plot and by using the Chi2-test and the I2 statistic. Sig-
nificant heterogeneity was present in case P < 010,
I2> 50% and no/limited overlap in the 95% confidence
intervals exists (visual inspection). If these criteria were
met, the meta-analysis was not carried out. Effect mea-
sures of association between sexual risk behaviour and
markers of transfusion-transmissible infections were
expressed as odds ratios (ORs) with or without adjust-
ment for confounding factors (i.e. adjusted ORs and
unadjusted ORs, respectively). By calculating log[OR] and
its corresponding standard error (standard error=(upper
limit of the 95% confidence interval – lower limit of the
95% confidence interval)/392), a random-effects model
was constructed using the generic inverse variance
method [10]. Firstly, the effect measures for each out-
come (HIV, HBC and HCV) were pooled (one effect mea-
sure per study) in different models (one model per
outcome). Secondly, different subgroup analyses (per
outcome) were conducted to explain potential hetero-
geneity across studies: (1) matched studies with adjust-
ment for confounding factors (via multivariate
regression analysis) versus unmatched studies without
adjusted effect measures (to explain the potential impact
of matched groups and considering confounding factors)
and (2) studies performed in European countries versus
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non-European countries (to serve as a basis for the cur-
rent European Directive). A P-value <005 was consid-
ered as statistically significant.
Results
Study selection
The systematic literature search resulted in a total of
2735 citations (after removing duplicates) which were
scrutinised by two reviewers independently. Figure 1 rep-
resents the study selection process used. We eventually
included 15 case–control studies comparing blood donors
that were tested positive for HCV antibodies (in 14 stud-
ies), HBV antibodies (in two studies) or HIV antibodies (in
one study) (cases) with donors that were seronegative for
any infectious marker (controls). No studies were identi-
fied that reported associations between sexual risk beha-
viour and Treponema pallidum.
Sixty percent (n = 9) of the case–control studies were
matched for age (n = 9), gender (n = 9), donor venue
(n = 6), donation status (n = 3), donation date (n = 2),
donation type (n = 1) and/or race/ethnicity (n = 1)
whereas the other 6 case–control studies (40%) were
unmatched. Mean age, gender and number of cases/con-
trols were reported in seven studies, 12 studies and 15
studies, respectively: cases (mean age 372 years, 64%
males, n = 4600) vs. controls (mean age 39.6 years, 62%
males, n = 8656). In all studies, a structured questionnaire
(via face-to-face/telephone interview or via email) dealing
with a list of potential risk factors (including factors
related to sexual risk behaviour) for HBV, HCV or HIV
transmission was used. These questionnaires included the
following sexual risk behaviour: sex with a drug user (12
studies), number of (lifetime) sexual partners (10 studies),
sex partner with hepatitis/HIV (five studies), paid or
received money for sex (four studies), sex with a blood
transfusion recipient (three studies), anal sex (two stud-
ies), sex with partner from HBV endemic area (one study),
orogenital sex (one study), sex during menstruation (one
study). According to the CDC statistics, the mean HBV
and HCV prevalence in the countries of included studies
was low (044% and 087%, respectively) (Table S1)
[11,12]. Five studies (33%) were published in the past ten
years (2008–2018), three (20%) in the period between
2000 and 2007 and seven (47%) before 2000. About half
of the included studies (47%) were conducted in the Euro-
pean region (United Kingdom (n = 3), Switzerland
(n = 1), Denmark (n = 1), Serbia (n = 1) and Sweden
(n = 1)). The other 8 studies were performed in the Amer-
ican regions ((Canada (n = 4) and USA (n = 3)) and in
Australia (n = 1). Details on the characteristics of the
included studies can be found in Table 1.
Association between sexual risk behaviour and
HBV infection
Two unmatched studies conducted in Danish HBsAg-posi-
tive donors and American anti-HBc positive donors (with-
out positive for HBV DNA) found that sexual risk
behaviour was significantly associated with HBV infection
(OR: 439, 95%CI[178, 1086], P = 0001 for paid sex;
OR: 621, 95%CI [250, 1543], P < 00001 for received
money or goods for sex; pooled OR: 902, 95%CI [286,
2849], P = 00002 for sex with an intravenous drug user;
pooled OR: 422, 95%CI [214, 832], P < 00001 for sex
partner with hepatitis; OR: 552, 95%CI [111, 2745],
P = 004 for sex partner with HIV). A statistically signifi-
cant association for the factors group sex or multiple sex
partners, sex partner from HBV endemic area or sex with
blood transfusion recipient could not be demonstrated
(Fig. 2) [13,14].
The evidence was graded as moderate for sex with an
intravenous drug user (upgraded (+2) for a large effect,
downgraded (-1) for indirectness); low for received
money or goods for sex and sex partner with hepatitis/
HIV (upgraded (+1) for a large effect, downgraded (-1)
for indirectness); low for paid sex (downgraded (-1) for
indirectness, upgraded (+1) for a large effect); very low
for group sex or multiple sex partners, sex partner from
HBV endemic area (downgraded for indirectness (-1) and
imprecision (-1)), and sex with a blood transfusion recipi-
ent (downgraded for indirectness (-1) and imprecision
(-1) and upgrade for a large effect (+1)) (Table S2).
Association between sexual risk behaviour and
HCV infection
Fourteen case–control studies investigated the association
between sexual risk behaviour and HCV infection and
found a significant association for the following behaviour:
received money or goods for sex (pooled OR: 578, 95%CI
[192, 1737], P = 0002); sex with an intravenous drug
user (pooled OR: 819, 95%CI [587, 1143], P < 000001);
sex partner with hepatitis (pooled OR: 484, 95%CI [232,
1007], P < 00001); orogenital sex (OR: 150, 95%CI [110,
205], P = 001); anal sex (OR: 171, 95%CI [121, 241],
P = 0002); sex during menstruation (OR: 242, 95%CI
[175, 335], P < 000001); and sex with a blood transfu-
sion recipient (pooled OR: 188, 95%CI [116, 303],
P = 001). A statistically significant association for the fol-
lowing sexual risk behaviour could not be demonstrated:
group sex or multiple sex partners (although a trend
towards an increased risk was observed), paid for sex and
sex partner with HIV (Fig. 3) [14–27].
Subgroup analyses revealed that the well-designed
case–control studies (i.e. matched groups and considering
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other confounding variables via a multivariate logistic
regression analysis) found a (statistically) significant rela-
tion with sexual risk behaviour (Fig. S1). These findings
were also observed in the matched case–control studies
without adjustment for confounding factors (Fig. S2). No
statistically significant associations were found in the
unmatched case–control studies with/without adjustment
for confounding factors, except for sex with an
intravenous drug user (Figs S3 and S4, respectively). Evi-
dence from the European studies showed a statistically
significant link with 1 sexual risk behaviour item (i.e. sex
with an intravenous drug user) whereas non-European
studies found 8 sexual risk behaviour items to be signifi-
cantly related to HCV infection (Figs S5 and S6).
The evidence was graded as moderate for received
money or goods for sex and sex with an intravenous drug
Fig. 1 Study identification and selection process of the systematic review.
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Fig. 2 HBV: study-specific odds ratios (ORs) representing the association between sexual risk behaviour and infection in blood donors. Each dot represents
the odds ratio of the respective study together with a 95% confidence interval (CI). The size of the box represents the weight of the study in the meta-analy-
sis. Weights are from random effects analysis. + Low risk of bias, – high risk of bias, ? unclear. [Colour figure can be viewed at wileyonlinelibrary.com]
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Fig. 3 HCV: study-specific odds ratios (ORs) representing the association between sexual risk behaviour and infection in blood donors. Each dot represents
the odds ratio of the respective study together with a 95% confidence interval (CI). The size of the box represents the weight of the study in the meta-analy-
sis. Weights are from random effects analysis. + Low risk of bias, – high risk of bias, ? unclear. [Colour figure can be viewed at wileyonlinelibrary.com]
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user [upgraded (+2) for a very large effect, downgraded (-
1) for indirectness]; low for sex partner with hepatitis
[upgraded (+1) for a large effect, downgraded (-1) for
indirectness]; low for paid for sex [downgraded (-1) for
indirectness, upgraded (+1) for a large effect] and anal
sex [downgraded (-1) for indirectness]; very low for sex
partner with HIV [downgraded for indirectness (-1) and
imprecision (-1)] and group sex or multiple sex partners,
origenital sex and sex during menstruation [downgraded
for imprecision (-1) and indirectness (-1)] (Table S3).
Association between sexual risk behaviour and
HIV infection
One unmatched case–control study conducted in Ameri-
can donors found that the following sexual risk beha-
viour was significantly associated, after controlling for
donor status, age, gender, race/ethnicity, income and
other risk factors (tattoo, piercing, injecting drug use,
MSM and detention): group sex or multiple sex partners
(OR: 230, 95%CI [140, 378]); received money or goods
for sex (OR: 520, 95%CI [140, 1932]; sex with an
intravenous drug user (OR: 1452, 95%CI [626, 3366]);
sex partner with hepatitis (OR: 316, 95%CI [132, 757])
and sex partner with HIV (OR: 13170, 95%CI [2670,
64956). A statistically significant difference in HIV infec-
tion for the risk factor sex with a blood transfusion recip-
ient could not be demonstrated (Fig. 4) [14].
The evidence was graded as very low for all sexual risk
behaviour [downgraded for indirectness (-1)] (Table S4).
Discussion
The present systematic review identified 15 case–control
studies that investigated the association between sexual
risk behaviour (excluding MSM) and TTIs in a Western
blood donor population. Meta-analyses showed that the
following sexual risk behaviour is probably linked to TTIs
(moderate certainty evidence): having sex with an intra-
venous drug user (HBV/HCV infection), received money
or goods for sex (HBV/HCV infection) or sex partner with
HIV (HBV infection). There may be an association
between a sex partner with hepatitis and HBV/HCV infec-
tion or between paid for sex and HBV infection (low
Fig. 4 HIV: study-specific odds ratios (ORs) representing the association between sexual risk behaviour and infection in blood donors. Each dot repre-
sents the odds ratio of the respective study together with a 95% confidence interval (CI). The size of the box represents the weight of the study in the
meta-analysis. Weights are from random effects analysis. + Low risk of bias, – high risk of bias, ? unclear. [Colour figure can be viewed at wileyonlinelib
rary.com]
© 2019 The Authors.
Vox Sanguinis published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion
Vox Sanguinis (2020) 115, 107–123
Link between sexual risk behaviour and TTIs 119
certainty evidence). We are uncertain whether other sex-
ual risk behaviour is associated with an increased HBV/
HCV/HIV infection risk (very low certainty evidence). No
studies were identified that reported associations between
sexual risk behaviour and Treponema pallidum.
The major strength of the present systematic review is
that it is the first review that used rigorous and transpar-
ent Cochrane methodology standards to investigate the
link between sexual risk behaviour, other than MSM, and
TTIs in a Western blood donor population. Moreover, we
were able to quantify the pooled effect estimates via dif-
ferent meta-analyses. Hereby, we improved statistical
power and precision (due to larger sample size), we quan-
tified inconsistencies in results between studies and con-
ducted appropriate subgroup analyses.
Three decades after the implementation of donor defer-
ral policies, sexual risk behaviour (especially MSM) has
been frequently discussed in the media, in the scientific
literature and among policy-makers. For example, Euro-
pean Union legislation (from 2004) distinguishes sexual
behaviour “at risk” and “at high risk” to define a tempo-
rary and permanent deferral from blood donation, respec-
tively [28]. A resolution of the European Committee of
Ministers concluded in 2013 that countries should only
introduce deferral policy for a given sexual behaviour
when having demonstrated that this sexual behaviour
does put the donors at high risk of acquiring blood-borne
infectious diseases [29]. Based on the best available evi-
dence [3,5,14,30–34], national regulatory bodies world-
wide have changed their recommendation from the
permanent deferral for MSM to a temporary deferral since
the last MSM contact (usually 12 months) [2].
In 2014, the US Food and Drug Administration (FDA)
concluded that for other sexual behaviour deferrals than
MSM, insufficient data are available to support a change
to their existing deferral recommendations [35]. There-
fore, the results of this review can be used as a scientific
basis for policy-makers to further scientifically underpin
the current international legislation concerning sexual
behaviour deferrals.
There are four limitations concerning the design and
publication date of the included studies, the selection cri-
teria of this review and the (non-)compliance of filling in
the medical questionnaire. Firstly, only observational data
from case–control studies were included in this review.
Causal associations are generally difficult to establish and
interpretation is limited by potential confounding effects
of other established risk factors such as the use of intra-
venous drugs, previous transfusion or percutaneous nee-
dle treatments (tattoo, acupuncture or piercing). Our
results showed that, after correction for these confound-
ing variables, the association between sexual risk beha-
viour and HCV infection was still present. Further studies
of higher quality are needed (e.g. prospective cohort stud-
ies) to gain a comprehensive understanding of the associ-
ation between sexual risk behaviour and TTIs. Secondly,
the data from this review were extracted from predomi-
nantly older studies (i.e. 80% of studies were conducted
before 2010) and only apply to a certain geographic area,
namely Western countries (Northern, Western and South-
ern Europe, USA, Canada, Australia and New Zealand).
Therefore, assuming that hygiene regulations and changes
in TTI prevalence improved over time, our data might
overestimate the current risk of sexual risk behaviour and
TTIs. In addition, because the epidemiology of sexual
transmissible diseases, sexual risk behaviour and hygiene
regulations are different in developing countries, the
results of this systematic review cannot be generalized.
Thirdly, searching in only three databases might serve as
a potential limitation, however, with the identification of
15 studies, the potential impact of additional evidence from
other databases or grey literature sources on our results/
conclusions is expected to be minimal. Finally, we did not
account for (non-)compliance in filling out the medical
questionnaire, as it is impossible to deduce from the studies
what percentage of donors were honest about sexual risk
behaviour. Further research about the impact of different
deferral strategies on non-compliance is needed.
Besides appropriate donor selection criteria, laboratory
testing, safe processing and appropriate use of blood are
also important to ensure that recipients receive the safest
possible blood products. Today, many blood banks have
implemented nucleic acid testing (NAT) in addition to
antibody testing for HBV/HCV/HIV, which reduced the
window period to less than 10 days and introduced stan-
dardization of procedures such that error rates in testing
are extremely low [36,37]. Nevertheless, all blood screen-
ing programs have limitations and absolute safety, in
terms of freedom from infectious risk, cannot be guaran-
teed. In order to establish effective national programs to
ensure quality-assured screening of donated blood for
TTIs, blood banks need to additionally invest in the safety
of the blood supply by developing evidence-based donor
selection criteria.
Conclusion
Evidence from a systematic review of 15 observational
studies showed that sexual risk behaviour (including hav-
ing sex with an intravenous drug user, receiving money
or goods for sex or having a sex partner with hepatitis/
HIV) is probably associated with an increased risk of
HBV/HCV infection in blood donors from Western and
Pacific countries. This review serves as a direct scientific
basis for blood donor deferral policies on sexual risk
behaviour.
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Supporting Information
Additional Supporting Information may be found in the online version of this article:
Fig. S1 Study-specific odds ratios (ORs) representing the association between sexual risk behaviour and HCV infection in
blood donors. Subgroup analysis: matched groups with adjustment for confounding factors. Each dot represents the odds
ratio of the respective study together with a 95% confidence interval (CI). The size of the box represents the weight of
the study in the meta-analysis. Weights are from random effects analysis.
Fig. S2 Study-specific odds ratios (ORs) representing the association between sexual risk behaviour and HCV infection in
blood donors. Subgroup analysis: matched groups without adjustment for confounding factors. Each dot represents the
odds ratio of the respective study together with a 95% confidence interval (CI). The size of the box represents the weight
of the study in the meta-analysis. Weights are from random effects analysis
Fig. S3 Study-specific odds ratios (ORs) representing the association between sexual risk behaviour and HCV infection in
blood donors. Subgroup analysis: unmatched groups with adjustment for confounding factors. Each dot represents the
odds ratio of the respective study together with a 95% confidence interval (CI). The size of the box represents the weight
of the study in the meta-analysis. Weights are from random effects analysis.
Fig. S4 Study-specific odds ratios (ORs) representing the association between sexual risk behaviour and HCV infection in
blood donors. Subgroup analysis: unmatched groups without adjustment for confounding factors. Each dot represents
the odds ratio of the respective study together with a 95% confidence interval (CI). The size of the box represents the
weight of the study in the meta-analysis. Weights are from random effects analysis.
Fig. S5 Study-specific odds ratios (ORs) representing the association between sexual risk behaviour and HCV infection in
blood donors. Subgroup analysis: studies conducted in European countries. Each dot represents the odds ratio of the
respective study together with a 95% confidence interval (CI). The size of the box represents the weight of the study in
the meta-analysis. Weights are from random effects analysis.
Fig. S6 Study-specific odds ratios (ORs) representing the association between sexual risk behaviour and HCV infection in
blood donors. Subgroup analysis: studies conducted in non-European countries. Each dot represents the odds ratio of
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the respective study together with a 95% confidence interval (CI). The size of the box represents the weight of the study
in the meta-analysis. Weights are from random effects analysis.
Table S1 HBV/HCV prevalence of the general population across countries of included studies (according to the CDC
statistics). N/A: not available.
Table S2 GRADE assessments for outcome HBV infection. CI:Confidence interval; OR: Odds ratio; a. Limited generaliz-
ibility: few and/or old studies; b. Large variability in results.
Table S3 GRADE assessments for outcome HCV infection. CI: Confidence interval; OR: Odds ratio; a. Limited generaliz-
ibility: few and/or old studies; b. Large variability in results.
Table S4 GRADE assessments for outcome HIV infection.
Appendix S1 PRISMA checklist.
Appendix S2 Detailed information on the search strategies in the different databases.
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